Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells.
Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW.
Biochem Pharmacol. 2012 Mar 1;83(5):586-97. Epub 2011 Dec 16.
Related citations
Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
Park B, Sung B, Yadav VR, Chaturvedi MM, Aggarwal BB.
Biochem Pharmacol. 2011 Nov 1;82(9):1134-44. Epub 2011 Jul 27.
Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.
Yoshida K, Nagai T, Ohmine K, Uesawa M, Sripayap P, Ishida Y, Ozawa K.
Biochem Pharmacol. 2011 Dec 15;82(12):1884-90. Epub 2011 Sep 29.
The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes.
Vande Voorde J, Liekens S, McGuigan C, Murziani PG, Slusarczyk M, Balzarini J.
Biochem Pharmacol. 2011 Sep 1;82(5):441-52. Epub 2011 May 31.
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E, Estañ MC, Simón GP, Sancho P, Boyano-Adánez Mdel C, de Blas E, Bréard J, Aller P.
Biochem Pharmacol. 2011 Dec 1;82(11):1619-29. Epub 2011 Aug 27.
Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique.
Zhang W, Tan S, Paintsil E, Dutschman GE, Gullen EA, Chu E, Cheng YC.
Biochem Pharmacol. 2011 Aug 15;82(4):411-7. Epub 2011 May 18.
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.
Lainey E, Thépot S, Bouteloup C, Sébert M, Adès L, Tailler M, Gardin C, de Botton S, Baruchel A, Fenaux P, Kroemer G, Boehrer S.
Biochem Pharmacol. 2011 Nov 15;82(10):1457-66. Epub 2011 Jun 1.
Reversible epigenetic fingerprint-mediated glutathione-S-transferase P1 gene silencing in human leukemia cell lines.
Karius T, Schnekenburger M, Ghelfi J, Walter J, Dicato M, Diederich M.
Biochem Pharmacol. 2011 Jun 1;81(11):1329-42. doi: 10.1016/j.bcp.2011.03.014. Epub 2011 Mar 29.
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS.
Biochem Pharmacol. 2011 Jan 15;81(2):222-32. Epub 2010 Oct 8.
Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia.
Tsumuraya T, Ishikawa C, Machijima Y, Nakachi S, Senba M, Tanaka J, Mori N.
Biochem Pharmacol. 2011 Mar 15;81(6):713-22. Epub 2011 Jan 8.
Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
Damaraju VL, Smith KM, Mowles D, Nowak I, Karpinski E, Young JD, Robins MJ, Cass CE.
Biochem Pharmacol. 2011 Jan 1;81(1):82-90. Epub 2010 Sep 18.
Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.
Bastin-Coyette L, Cardoen S, Smal C, de Viron E, Arts A, Amsailale R, Van Den Neste E, Bontemps F.
Biochem Pharmacol. 2011 Mar 1;81(5):586-93. Epub 2010 Dec 17.
Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Rakshit S, Mandal L, Pal BC, Bagchi J, Biswas N, Chaudhuri J, Chowdhury AA, Manna A, Chaudhuri U, Konar A, Mukherjee T, Jaisankar P, Bandyopadhyay S.
Biochem Pharmacol. 2010 Dec 1;80(11):1662-75. Epub 2010 Sep 9.
JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.
Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Keefer LK, Kashfi K.
Biochem Pharmacol. 2010 Dec 1;80(11):1641-9. Epub 2010 Aug 24.
Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy.
Schnekenburger M, Grandjenette C, Ghelfi J, Karius T, Foliguet B, Dicato M, Diederich M.
Biochem Pharmacol. 2011 Feb 1;81(3):364-78. Epub 2010 Oct 31.
UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells.
Juncker T, Cerella C, Teiten MH, Morceau F, Schumacher M, Ghelfi J, Gaascht F, Schnekenburger M, Henry E, Dicato M, Diederich M.
Biochem Pharmacol. 2011 Jan 1;81(1):13-23. Epub 2010 Sep 21.
A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).
Saiko P, Graser G, Giessrigl B, Lackner A, Grusch M, Krupitza G, Basu A, Sinha BN, Jayaprakash V, Jaeger W, Fritzer-Szekeres M, Szekeres T.
Biochem Pharmacol. 2011 Jan 1;81(1):50-9. Epub 2010 Sep 16.
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
Nair RR, Tolentino J, Hazlehurst LA.
Biochem Pharmacol. 2010 Sep 1;80(5):602-12. Epub 2010 Apr 9. Review.
Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
Eriksson A, Höglund M, Lindhagen E, Aleskog A, Hassan SB, Ekholm C, Fhölenhag K, Jensen AJ, Löthgren A, Scobie M, Larsson R, Parrow V.
Biochem Pharmacol. 2010 Nov 15;80(10):1507-16. Epub 2010 Aug 10.
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.
Chen LS, Balakrishnan K, Gandhi V.
Biochem Pharmacol. 2010 Dec 15;80(12):1936-45. Epub 2010 Aug 7. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on